Sunbeam Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.81M Buy
3,175
+36
+1% +$36.8K 1.74% 11
2026
Q1
$2.89M Buy
3,139
+733
+30% +$743K 1.65% 12
2025
Q4
$2.59M Buy
2,406
+17
+0.7% +$16.3K 1.53% 15
2025
Q3
$1.82M Buy
2,389
+61
+3% +$45.4K 1.13% 19
2025
Q2
$1.81M Buy
2,328
+503
+28% +$391K 1.37% 18
2025
Q1
$1.51M Buy
1,825
+2
+0.1% +$1.66K 1.44% 16
2024
Q4
$1.41M Buy
+1,823
New +$1.51M 1.31% 21

Other funds holding LLY

Sunbeam Capital Management's LLY Position: Q2 2026 in Review

Sunbeam Capital Management increased its Eli Lilly (LLY) stake by 1.1% in Q2 2026, buying an estimated $36.8K and bringing the position to 3,175 shares worth $3.81M. The position accounts for 1.74% of the portfolio, ranked #11.

Sunbeam Capital Management first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 2,241 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Sunbeam Capital Management held 3,175 shares of Eli Lilly worth $3.81M as of Q2 2026.
  • Sunbeam Capital Management bought 36 Eli Lilly shares in Q2 2026, an estimated $36.8K.
  • Eli Lilly made up 1.74% of Sunbeam Capital Management's portfolio in Q2 2026, its #11 holding.
  • Sunbeam Capital Management first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 2,241 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Sunbeam Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.